X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
index medicus (18) 18
cardiac & cardiovascular systems (11) 11
acute coronary syndromes (8) 8
risk factors (7) 7
treatment outcome (7) 7
anticoagulants - therapeutic use (6) 6
atrial fibrillation (6) 6
medical and health sciences (6) 6
medicin och hälsovetenskap (6) 6
abridged index medicus (5) 5
acute coronary syndrome (5) 5
anticoagulants (5) 5
anticoagulants - adverse effects (5) 5
female (5) 5
hematology (5) 5
male (5) 5
myocardial-infarction (5) 5
peripheral vascular disease (5) 5
thrombosis - prevention & control (5) 5
antithrombotic therapy (4) 4
bleeding (4) 4
cardiac and cardiovascular systems (4) 4
coronary heart disease (4) 4
elevation myocardial-infarction (4) 4
heart diseases - drug therapy (4) 4
kardiologi (4) 4
low-dose aspirin (4) 4
myocardial infarction (4) 4
thrombosis (4) 4
thrombosis - drug therapy (4) 4
acute coronary syndrome - drug therapy (3) 3
acute myocardial-infarction (3) 3
administration, oral (3) 3
anticoagulants - administration & dosage (3) 3
antiplatelet therapy (3) 3
atherosclerosis (3) 3
atrial fibrillation - complications (3) 3
blood coagulation - drug effects (3) 3
cardiology (3) 3
cardiology - standards (3) 3
cardiovascular diseases - prevention & control (3) 3
cholesterol (3) 3
coagulation (3) 3
dual antiplatelet therapy (3) 3
europe (3) 3
heart diseases (3) 3
heart diseases - blood (3) 3
hemorrhage - prevention & control (3) 3
percutaneous coronary intervention (3) 3
platelet aggregation inhibitors - therapeutic use (3) 3
risk assessment (3) 3
sex factors (3) 3
societies, medical (3) 3
statins (3) 3
time factors (3) 3
vitamin k antagonists (3) 3
1102 cardiovascular medicine and haematology (2) 2
acute coronary syndrome - blood (2) 2
acute coronary syndrome - complications (2) 2
acute coronary syndrome - diagnosis (2) 2
acute coronary syndrome - therapy (2) 2
advisory committees (2) 2
age factors (2) 2
animals (2) 2
antibodies, monoclonal - adverse effects (2) 2
anticholesteremic agents - adverse effects (2) 2
apixaban (2) 2
artery-disease (2) 2
atrial fibrillation - blood (2) 2
atrial fibrillation - drug therapy (2) 2
atrial fibrillation - epidemiology (2) 2
atrial-fibrillation patients (2) 2
bias (2) 2
cardiology and cardiovascular medicine (2) 2
cardiology and cardiovascular system (2) 2
cardiovascular (2) 2
cardiovascular disease (2) 2
cardiovascular diseases - blood (2) 2
cardiovascular system & hematology (2) 2
clinical classification schemes (2) 2
clinical medicine (2) 2
clinical trials (2) 2
clinical trials as topic (2) 2
coronary artery disease - drug therapy (2) 2
coronary-heart-disease (2) 2
current opinion (2) 2
dabigatran etexilate (2) 2
double-blind method (2) 2
drug-eluting stents (2) 2
edoxaban (2) 2
efficacy (2) 2
factor xa inhibitor (2) 2
fibrinolytic agents - adverse effects (2) 2
fibrinolytic agents - therapeutic use (2) 2
forecasting (2) 2
heart attacks (2) 2
heart disease (2) 2
heart failure (2) 2
hemorrhage (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 2010, Volume 31, Issue 23, pp. 2844 - 2853
Journal Article
European heart journal, ISSN 0195-668X, 2011, Volume 32, Issue 11, pp. 1345 - 1361
Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper... 
Remnants | Triglyceride-rich lipoproteins | Atherosclerosis | Atherogenic dyslipidaemia | Cardiovascular disease | Triglycerides | High-density lipoprotein cholesterol | Cholesterol | Guidelines | INTIMA-MEDIA THICKNESS | METABOLIC SYNDROME | CARDIAC & CARDIOVASCULAR SYSTEMS | ESTER TRANSFER PROTEIN | HEALED MYOCARDIAL-INFARCTION | HDL-CHOLESTEROL | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | EXTENDED-RELEASE NIACIN | APOLIPOPROTEIN-A-I | ARTERY-DISEASE | Cardiovascular Diseases - etiology | Fibric Acids - therapeutic use | Life Style | Dyslipidemias - complications | Cholesterol, HDL - metabolism | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Lipid Metabolism | Clinical Trials as Topic | Forecasting | Triglycerides - metabolism | Dyslipidemias - blood | Niacin - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lipoproteins - metabolism | Cardiovascular Diseases - blood | Fatty Acids, Omega-3 - therapeutic use | Dyslipidemias - prevention & control | Hypolipidemic Agents - therapeutic use | Current Opinion | Kardiologi | atherosclerosis | cardiovascular disease | Cardiac and Cardiovascular Systems | high-density lipoprotein cholesterol | remnants | cholesterol | guidelines | triglycerides | atherogenic dyslipidaemia | triglyceride-rich lipoproteins
Journal Article
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 2015, Volume 8, Issue 1, pp. 201 - 213
Abstract Objectives The aim of this meta-analysis was to compare the 30-day safety and efficacy of bivalirudin with those of heparin with or without routine... 
Cardiovascular | heparin | meta-analysis | GP IIb/IIIa inhibitor | acute coronary syndrome | bivalirudin | Bivalirudin | Heparin | Acute coronary syndrome | Meta-analysis | CARDIAC & CARDIOVASCULAR SYSTEMS | THROMBOSIS | BARE-METAL STENTS | STRATEGY | RISK | TRIAL | OUTCOMES | INTERVENTION | ELEVATION MYOCARDIAL-INFARCTION | UNFRACTIONATED HEPARIN | PLUS | Recombinant Proteins - therapeutic use | Humans | Acute Coronary Syndrome - mortality | Heparin - therapeutic use | Recombinant Proteins - adverse effects | Heparin - adverse effects | Time Factors | Platelet Glycoprotein GPIIb-IIIa Complex - metabolism | Coronary Thrombosis - prevention & control | Blood Platelets - drug effects | Odds Ratio | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Platelet Aggregation Inhibitors - adverse effects | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Chi-Square Distribution | Acute Coronary Syndrome - blood | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Blood Platelets - metabolism | Hirudins - adverse effects | Acute Coronary Syndrome - diagnosis | Coronary Thrombosis - etiology | Myocardial Infarction - prevention & control | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced
Journal Article
Journal Article
Journal Article